Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine - A Staccato trial substudy

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1340-1343

  Ananworanich, Jintanat ^a,b   Nuesch, Reto ^c   Côté, Hélène C F ^d   Kerr, Stephen J ^a,e   Hill, Andrew ^f   Jupimai, Thidarat ^a   Laopraynak, Naphassanant ^a   Saenawat, Sukontha ^a   Ruxrungtham, Kiat ^a,g   Hirschel, Bernard ^h  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b South East Asia Research Collaboration with Hawaii ^*  (Thailand)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Mitochondrial toxicity; NRTIs; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CELL NUCLEUS DNA; DIDANOSINE PLUS STAVUDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS TENOFOVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; MALE; METABOLIC DISORDER; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL TOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THAILAND; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ABSORPTIOMETRY, PHOTON; ADENINE; ADULT; ANTI-HIV AGENTS; BODY FAT DISTRIBUTION; DIDANOSINE; DNA, MITOCHONDRIAL; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIPIDS; LIVER FUNCTION TESTS; PHOSPHONIC ACIDS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; STAVUDINE; THAILAND;

EID: 44449163367     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn097     Document Type: Article

References (21)

1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
2. Buffet M, Schwarzinger M, Amellal B et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol 2005; 33: 60-4.
3. Nolan D, Hammond E, James I et al. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8: 617-26.
4. Petit C, Mathez D, Barthelemy C et al. Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. J Acquir Immune Defic Syndr 2003; 33: 461-9.
5. Cherry CL, Nolan D, James IR et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 2006; 42 435-40.
6. Saitoh A, Fenton T, Alvero C et al. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007; 51: 4236-42.
7. Maagaard A, Holberg-Petersen M, Kollberg G et al. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006; 11: 601-8.
8. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
9. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
10. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
11. Parker R, Komarow L, Grinspoon S et al. Baseline and early on-treatment predictors of lipoatrophy at 64 weeks in a randomized trial of initial antiretroviral therapy: A secondary analysis of A5005s, a sub-study of ACTG 384. Antivir Ther 2005; 10: L5.
12. Hill A, Ruxrungtham K, Hanvanich M et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8: 679-88.
13. Ananworanich J, Hill A, Siangphoe U et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther 2005; 10: 761-7.
14. Ananworanich J, Gayet-Ageron A, Le Braz M et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial. Lancet 2006; 368: 459-65.
15. Cote HC, Brumme ZL, Craib KJ et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811-20.
16. Cote HC, Yip B, Asselin JJ et al. Mitochondrial:nUclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003; 187: 1972-6.
17. Miro O, Garrabou G, Lopez S et al. Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir. Antivir Ther 2006; 11: 625-30.
18. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002; 288: 207-15.
19. Valdez JR, Cassetti I, Suleiman JM et al. The safety and efficacy of switching stavudine to tenofovir DF in combination with lamivudine and efavirenz in HIV-1-infected patients: Three-year follow-up after switching therapy. HIV Clin Trials 2007; 8: 381-90.
20. Calmy A, Pinoges L, Szumilin E et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20: 1163-9.
21. The Clinton Foundation. Clinton HIV AIDS Initiative: 2007 Antiretroviral Drug Price List. http://www.clintonfoundation.org/pdf/ chai-arv-price-list-050807.pdf (1 August 2007, date last accessed).